Clinical proof-of-concept trial of RX 5902 (Supinoxin) in patients with cancer

Trial Profile

Clinical proof-of-concept trial of RX 5902 (Supinoxin) in patients with cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs RX 5902 (Primary)
  • Indications Breast cancer; Cancer; Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 23 Feb 2017 According to a Rexahn Pharmaceuticals media release, the preliminary readout from this study anticipated later in 2017.
    • 23 Feb 2017 According to a Rexahn Pharmaceuticals media release, first patient has been dosed in this phase IIa study.
    • 23 Feb 2017 Status changed from planning to recruiting, according to a Rexahn Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top